Logotipo do repositório
 

Publicação:
Hospitalization costs of coronaviruses diseases in upper-middle-income countries: A systematic review

dc.contributor.authorRocha-Filho, César Ramos
dc.contributor.authorMartins, Johnny Wallef Leite [UNESP]
dc.contributor.authorLucchetta, Rosa Camila [UNESP]
dc.contributor.authorRamalho, Gabriel Sodré
dc.contributor.authorTrevisani, Giulia Fernandes Moça
dc.contributor.authorda Rocha, Aline Pereira
dc.contributor.authorPinto, Ana Carolina Pereira Nunes
dc.contributor.authorde Assis Reis, Felipe Sebastião
dc.contributor.authorFerla, Laura Jantsch
dc.contributor.authorde Carvalho Mastroianni, Patrícia [UNESP]
dc.contributor.authorCorrea, Luci
dc.contributor.authorSaconato, Humberto
dc.contributor.authorTrevisani, Virgínia Fernandes Moça
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionHospital Alemão Oswaldo Cruz
dc.contributor.institutionUniversidade de Santo Amaro
dc.contributor.institutionUniversidade Federal do Amapá
dc.contributor.institutionBeneficência Portuguesa de São Paulo
dc.date.accessioned2022-04-29T08:40:48Z
dc.date.available2022-04-29T08:40:48Z
dc.date.issued2022-03-01
dc.description.abstractBackground COVID-19, SARS and MERS are diseases that present an important health burden worldwide. This situation demands resource allocation to the healthcare system, affecting especially middle- and low-income countries. Thus, identifying the main cost drivers is relevant to optimize patient care and resource allocation. Objective To systematically identify and summarize the current status of knowledge on direct medical hospitalization costs of SARS, MERS, or COVID-19 in Upper-Middle-Income Countries. Methods We conducted a systematic review across seven key databases (PubMed, EMBASE, BVS Portal, CINAHL, CRD library, MedRxiv and Research Square) from database inception to February 2021. Costs extracted were converted into 2021 International Dollars using the Purchasing Power Parity-adjusted. The assessment of quality was based on the protocol by the BMJ and CHEERS. PROSPERO 2020: CRD42020225757. Results No eligible study about SARS or MERS was recovered. For COVID-19, five studies presented cost analysis performed in Brazil, China, Iran, and Turkey. Regarding total direct medical costs, the lowest cost per patient at ward was observed in Turkey ($900.08), while the highest in Brazil ($5,093.38). At ICU, the lowest was in Turkey ($2,984.78), while the highest was in China ($52,432.87). Service care was the most expressive (58% to 88%) cost driver of COVID-19 patients at ward. At ICU, there was no consensus between service care (54% to 87%) and treatment (72% to 81%) as key burdens of total cost. Conclusion Our findings elucidate the importance of COVID-19 on health-economic outcomes. The marked heterogeneity among studies leaded to substantially different results and made challenging the comparison of data to estimate pooled results for single countries or regions. Further studies concerning cost estimates from standardized analysis may provide clearer data for a more substantial analysis. This may help care providers and policy makers to organize care for patients in the most efficient way.en
dc.description.affiliationEvidence-Based Health Program Escola Paulista de Medicina Universidade Federal de São Paulo, SP
dc.description.affiliationPharmaceutical Sciences Program School of Pharmaceutical Sciences Universidade Estadual de São Paulo, SP
dc.description.affiliationDepartment of Drugs and Medicines School of Pharmaceutical Sciences Universidade Estadual de São Paulo, SP
dc.description.affiliationDepartment of Sustainability and Social Responsibility Hospital Alemão Oswaldo Cruz, SP
dc.description.affiliationEscola Paulista de Medicina Universidade Federal de São Paulo, SP
dc.description.affiliationFaculdade de Medicina Universidade de Santo Amaro, SP
dc.description.affiliationDepartment of Biological and Health Sciences Universidade Federal do Amapá, AP
dc.description.affiliationDepartment of Medical Practices Beneficência Portuguesa de São Paulo, SP
dc.description.affiliationDiscipline of Infectiology Escola Paulista de Medicina Universidade Federal de São Paulo, SP
dc.description.affiliationDiscipline of Emergency and Evidence-Based Medicine Escola Paulista de Medicina Universidade Federal de São Paulo, SP
dc.description.affiliationUnespPharmaceutical Sciences Program School of Pharmaceutical Sciences Universidade Estadual de São Paulo, SP
dc.description.affiliationUnespDepartment of Drugs and Medicines School of Pharmaceutical Sciences Universidade Estadual de São Paulo, SP
dc.identifierhttp://dx.doi.org/10.1371/journal.pone.0265003
dc.identifier.citationPLoS ONE, v. 17, n. 3 March, 2022.
dc.identifier.doi10.1371/journal.pone.0265003
dc.identifier.issn1932-6203
dc.identifier.scopus2-s2.0-85126282869
dc.identifier.urihttp://hdl.handle.net/11449/230570
dc.language.isoeng
dc.relation.ispartofPLoS ONE
dc.sourceScopus
dc.titleHospitalization costs of coronaviruses diseases in upper-middle-income countries: A systematic reviewen
dc.typeResenhapt
dspace.entity.typePublication
relation.isDepartmentOfPublicatione214da1b-9929-4ae9-b8fd-655e9bfeda4b
relation.isDepartmentOfPublication.latestForDiscoverye214da1b-9929-4ae9-b8fd-655e9bfeda4b
unesp.departmentFármacos e Medicamentos - FCFpt

Arquivos